Life Biosciences secures an $80M Series D as its ER-100 trial gets under way

Life Biosciences/ER-100

Life Biosciences closed a fully subscribed $80M Series D to fund operations into 2H 2027, including completion of its Phase 1 trial of ER-100 and further work on its partial epigenetic reprogramming platform.

• Series D funds operations through second half of 2027, supporting Phase 1 ER-100 completion and platform expansion.
• ER-100 Phase 1 in optic neuropathies initiated Q1 2026; trial evaluates safety, tolerability and visual function changes.
• Platform targets multiple therapeutic areas using partial epigenetic reprogramming to restore youthful cell function.